Show simple item record

dc.contributor.authorMoynihan, Kelly Dare
dc.contributor.authorIrvine, Darrell J
dc.date.accessioned2018-09-07T20:35:52Z
dc.date.available2018-09-07T20:35:52Z
dc.date.issued2017-10
dc.identifier.issn0008-5472
dc.identifier.issn1538-7445
dc.identifier.urihttp://hdl.handle.net/1721.1/117685
dc.description.abstractImmunity to infectious agents involves a coordinated response of innate and adaptive immune cells working in concert, with many feed-forward and regulatory interactions between both arms of the immune system. In contrast, many therapeutic strategies to augment immunity against tumors have focused predominantly on stimulation of adaptive immunity. However, a growing appreciation of the potential contributions of innate immune effectors to antitumor immunity, especially in the context of combination immunotherapy, is leading to novel strategies to elicit a more integrated immune response against cancer. Here we review antitumor activities of innate immune cells, mechanisms of their synergy with adaptive immune responses against tumors, and discuss recent studies highlighting the potential of combination therapies recruiting both innate and adaptive immune effectors to eradicate established tumors.en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (CA174795)en_US
dc.description.sponsorshipNational Cancer Institute (U.S.) (David H. Koch Institute for Integrative Cancer Research at MIT. Grant P30-CA14051)en_US
dc.description.sponsorshipBridge Projecten_US
dc.description.sponsorshipV Foundation for Cancer Researchen_US
dc.description.sponsorshipRagon Institute of MGH, MIT and Harvarden_US
dc.description.sponsorshipHertz Foundationen_US
dc.description.sponsorshipNational Science Foundation (U.S.) (Graduate Research Fellowship)en_US
dc.description.sponsorshipThomas and Stacey Siebel Foundation (Scholarship)en_US
dc.publisherAmerican Association for Cancer Research (AACR)en_US
dc.relation.isversionofhttp://dx.doi.org/10.1158/0008-5472.CAN-17-1340en_US
dc.rightsCreative Commons Attribution-Noncommercial-Share Alikeen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/en_US
dc.sourcePMCen_US
dc.titleRoles for Innate Immunity in Combination Immunotherapiesen_US
dc.typeArticleen_US
dc.identifier.citationMoynihan, Kelly D., and Darrell J. Irvine. “Roles for Innate Immunity in Combination Immunotherapies.” Cancer Research, vol. 77, no. 19, Oct. 2017, pp. 5215–21.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Center for Materials Science and Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Materials Science and Engineeringen_US
dc.contributor.departmentRagon Institute of MGH, MIT and Harvarden_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.mitauthorMoynihan, Kelly Dare
dc.contributor.mitauthorIrvine, Darrell J
dc.relation.journalCancer Researchen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2018-09-06T18:11:24Z
dspace.orderedauthorsMoynihan, Kelly D.; Irvine, Darrell J.en_US
dspace.embargo.termsNen_US
mit.licenseOPEN_ACCESS_POLICYen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record